Share Email Print
cover

Proceedings Paper

Low dose Photofrin PDT for recurrent in-situ squamous cell tumors of the head and neck
Author(s): R. R Allison; C. Austerlitz; C. Sheng; H. Mota; B. Brodish; P. Camnitz; C. H. Sibata
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Multifocal recurrence of in-situ squamous cell cancer of the oral cavity, pharynx and vocal cord following surgical failure can be a therapeutic dilemma. Salvage surgery or radiation may be an option but morbidity can be significant. We evaluated the potential role of low dose Photofrin (1.2mg/Kg) Photodynamic Therapy for this cohort of patients. A total of 25 patients with multifocal recurrent in-situ squamous cell cancer of the oral cavity, pharynx and vocal cord who had failed local resection, and where additional surgery or radiation therapy would likely result in permanent morbidity, were offered Photodynamic Therapy. PDT consisted of off label infusion of Photofrin (1.2mg/kg) followed 48 hours later by illumination at 630nm employing a light diffuser (300J) and/or microlens (150Jcm2). All patients completed their prescribed PDT and no patient has been lost to follow up (minimum 1 year). No photosensitivity reactions were noted. No significant morbidity was seen. All patients were able to maintain oral nutrition. Procedure related pain was well controlled by one week of oral narcotics. At one month post PDT all patients were biopsy negative in the treatment region and no failures within the treatment region have been noted. No fibrosis or permanent PDT morbidity has been seen with follow up to three years. Vocal cord and voice function were excellent. Three patients developed new regions of in-situ disease outside the PDT fields, two underwent additional PDT and one had laser resection. Low dose Photofrin PDT offers excellent palliation and durable local control of recurrent in-situ squamous cell cancers of the oral cavity, pharynx and true cords. This is a well tolerated therapy. Low dose Photofrin appears to improve selectivity and minimize normal tissue injury. It should be tested in a larger patient population.

Paper Details

Date Published: 13 July 2009
PDF: 6 pages
Proc. SPIE 7380, Photodynamic Therapy: Back to the Future, 73801R (13 July 2009); doi: 10.1117/12.822259
Show Author Affiliations
R. R Allison, Brody School of Medicine at East Carolina Univ. (United States)
C. Austerlitz, Brody School of Medicine at East Carolina Univ. (United States)
C. Sheng, Brody School of Medicine at East Carolina Univ. (United States)
H. Mota, Brody School of Medicine at East Carolina Univ. (United States)
B. Brodish, Brody School of Medicine at East Carolina Univ. (United States)
P. Camnitz, Brody School of Medicine at East Carolina Univ. (United States)
C. H. Sibata, Brody School of Medicine at East Carolina Univ.. (United States)


Published in SPIE Proceedings Vol. 7380:
Photodynamic Therapy: Back to the Future
David H. Kessel, Editor(s)

© SPIE. Terms of Use
Back to Top